Clinical Trials Browser

Has results × Hodgkin Disease × Panobinostat × Clear all

NCT00742027 2021-07-28

Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma

Phase 2 Completed

129 enrolled 16 charts

Hodgkin Disease

NCT01169636 2021-01-06

Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma

Phase 1/2 Completed

62 enrolled 13 charts

Hodgkin Disease

NCT00918333 2020-03-10

Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma

Phase 1/2 Completed

124 enrolled 10 charts

DermatologicLymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT01460940 2017-11-14

A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Phase 2 Completed

24 enrolled 7 charts

Hodgkin Disease

NCT01034163 2016-07-07

PATH

Phase 3 Completed

41 enrolled 7 charts

Hodgkin Disease

NCT00967044 2015-02-26

Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma

Phase 1/2 Completed

31 enrolled 6 charts

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Recurrence